Health Bulletin 10/December/2021 - Video
Overview
Here are Top Health stories of the day
Delay in Diagnosis Increases Severity of Condition: Kerala Hospital told to pay Compensation
The District Consumer Disputes Redressal Commission recently directed the Kerala Medical College Hospital to pay an amount of Rs 50,000 as compensation to a patient over delay in diagnosis.
The patient was suffering from several complications including Acute Meningo Encephalitis, severe Hyponatremia, Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and Non-Insulin-Dependant Diabetes Mellitus (NIDDM). However, due to the delay in diagnosis of the condition the complainant had to face several complications.
For more details, check out the full story on the link below:
Delay In Diagnosis Increases Severity Of Condition: Kerala Hospital Told To Pay Compensation
WHO worry over Omicron
Health Ministry gives breakup of Oncology seats in India to Parliament
Currently, there are a total of 958 seats in the country offering PG medical training at Broad Specialty and Super Specialty level with different Oncology related specialisations.
The information to this effect comes from the data shared by the MoS Health Dr Bharati Pravin Pawar before the Parliament during question hour.
For more deatisl, check out the full story on the link below:
Health Ministry Gives Breakup Of Oncology Seats In India To Parliament
NEET 2021: Father-Daughter Duo Arrested for paying Rs 50 lakh for MBBS seat, Involvement with Solver Gang
Busting a NEET solver gang scam, the Varanasi Police have recently arrested a father-daughter duo hailing from Tripura in this connection.
An investigation has revealed that the man had approached the members of the solver gang for ensuring his daughter's admission to the MBBS course. For this, he had allegedly paid Rs 50 lakh, reports News 18.
For more details, check out the full story on the link below:
AstraZeneca's Evusheld gets USFDA approval for prevention of COVID-19
AstraZeneca has recently announced that Evusheld (tixagevimab co-packaged with cilgavimab), a Long-Acting Antibody (LAAB) combination, has received Emergency Use Authorisation (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.
The Food and Drug Administration (FDA) granted the EUA for Evusheld for pre-exposure prophylaxis of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination, as well as those individuals for whom COVID-19 vaccination is not recommended. Recipients should not be currently infected with or had recent known exposure to a person infected with SARS-CoV-2.
For more details, check out the full story on the link below:
Speakers
